About kiora pharmaceuticals - KPRX
Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.
KPRX At a Glance
Kiora Pharmaceuticals, Inc.
169 Saxony Road
Encinitas, California 92024
| Phone | 1-858-224-9600 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -10,835,154.00 | |
| Sector | Health Technology | Employees | 13 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
KPRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.46 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.902 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.043 |
KPRX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -833,473.385 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
KPRX Liquidity
| Current Ratio | 5.989 |
| Quick Ratio | 5.989 |
| Cash Ratio | 4.706 |
KPRX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -35.678 |
| Return on Equity | -51.736 |
| Return on Total Capital | -65.688 |
| Return on Invested Capital | -51.444 |
KPRX Capital Structure
| Total Debt to Total Equity | 2.284 |
| Total Debt to Total Capital | 2.233 |
| Total Debt to Total Assets | 1.518 |
| Long-Term Debt to Equity | 1.264 |
| Long-Term Debt to Total Capital | 1.236 |